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Most current articleInfections are life-threatening to patients with acute decompensation and acute-on-chronic
liver failure (AD/ACLF). Patients with AD/ACLF have prostaglandin E2–mediated immune
suppression, which can be reversed by administration of albumin; infusion of 20% human al-
bumin solution (HAS) might improve outcomes of infections. We performed a feasibility study
to determine optimal trial design, assess safety, and validate laboratory assessments of immune
function to inform design of a phase 3 trial.METHODS: We performed a prospective multicenter, single-arm, open-label trial of 79 patients with AD/
ACLF and levels of albumin lower than 30 g/L, seen at 10 hospitals in the United Kingdom from
May through December 2015. Patients were given daily infusions of 20% HAS, based on serum
levels, for 14 days or until discharge from the hospital. Rates of infection, organ dysfunction,
and in-hospital mortality were recorded. The primary end point was daily serum albumin level
during the treatment period. Success would be demonstrated if 60% achieved and maintained
serum albumin levels at or above 30 g/L on at least one third of days with recorded levels.RESULTS: The patients’ mean model for end-stage disease score was 20.9 – 6.6. The primary end point
(albumin ‡30 g/L on at least one third of days recorded) was achieved by 68 of the 79 patients;
75% of administrations were in accordance with suggested dosing regimen. Mean treatment
duration was 10.3 days (104 – 678 mL administered). There were 8 deaths and 13 serious
adverse events, considered by the independent data-monitoring committee to be consistent
with those expected. Twelve of 13 patients that developed either respiratory or cardiovascular
dysfunction (based on ward-based clinical deﬁnitions) as their only organ dysfunction were
alive at 30 days compared with 1 of 3 that developed renal dysfunction. Only 1 case of brain
dysfunction was recorded.CONCLUSIONS: In a feasibility trial, we found that administration of HAS increased serum levels of albumin in
patientswithAD/ACLF. Thedosing regimenwas acceptable atmultiple sites anddeemedsafe by an
independent data-monitoring committee. We also developed a robust system to record infections.
The poor prognosis for patients with renal dysfunction was conﬁrmed. However, patients with
cardiovascular or respiratory dysfunction had good outcomes, which is counterintuitive. Severe
encephalopathy appeared substantially under-reported, indicating thatward-based assessment of
these parameters cannot be recorded with sufﬁcient accuracy for use as a primary outcome in
phase 3 trials. Trial registration no: EudraCT 2014-002300-24 and ISRCTN14174793.Keywords: Cirrhosis; Treatment; Mortality; Immune Response.r: ACLF, acute-on-chronic liver failure; AD,
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Liver disease represents 2% to 3% of deathsglobally1,2 and was estimated to be responsible for
more than 1 million deaths in 2010.1 Incidence rates are
predicted to double over the next 20 years.3
Cirrhosis patients with liver failure are termed acute
decompensation (AD) or acute-on-chronic-liver failure4
(ACLF). They are highly prone to bacterial infection5,6
secondary to immune dysfunction,7 with nosocomial
infection rates of 35% compared with 5% in noncirrhotic
patients.8 Bacterial infection with organ dysfunction
carries a mortality risk ranging from 60% to 95%.9,10
Currently, there is no immune-restorative treatment for
patients with AD/ACLF.
Intravenous albumin is used commonly in patients
with AD/ACLF as a volume expander11–13 and has been
proven to prevent and improve renal failure.14,15 Many
hepatologists believe it has additional properties,16
however, no multicenter evidence exists for these puta-
tive properties and critical-care studies have failed to
establish a role.17
In our previous work, we showed that increased
circulating prostaglandin E2 (PGE2) was a potential key
immune-suppressive mediator in AD.18 We also devel-
oped an immune assay to assess the effects of patient
plasma on healthy monocyte-derived macrophage tumor
necrosis factor (TNF) production because monocyte
deactivation is a key feature of AD/ACLF and reduced
monocyte TNF production predicts poor outcomes in
sepsis.11 We recently showed, using a whole-blood
stimulation assay, a reduction in TNF production by
fresh circulating monocytes taken from ACLF patients.
These data match our observations made when
monocyte-derived macrophages are treated with AD/
ACLF plasma, validating our approach.12 The only clinical
characteristic that predicted immune suppression using
this approach was a serum albumin value less than 30 g/
L. Albumin has been reported to bind and catalyze
inactivation of PGE2,
13 and both circulating levels and
binding capacity19 decrease in AD/ACLF, making PGE2
potentially more bioavailable. In our pilot study, ex vivo
immune function improved after 20% human albumin
solution (HAS) transfusions.18 Therefore, we hypothesized
that infusing albumin in hospitalized AD/ACLF patients
with a serum albumin value less than 30 g/L with a target
to increase this value to 35 g/L or higher would improve
immune function, prevent new infections, and thus
improve mortality. In view of the current discrepancies in
ACLF deﬁnition20 we believed that large-scale recruitment
required simple inclusion criteria and wished to test
whether basing these on a serum albumin level less than
30 g/L would select appropriate patients.
There were several other uncertainties regarding our
protocol that required clariﬁcation before embarking on a
large, randomized controlled trial (RCT) comparingalbumin infusions with standard care. These included the
use of a 72-hourwindow from admission to treatment, our
end point deﬁnitions, and obtaining daily data and sample
collection. Furthermore, only 1 previous UK multicenter
interventional AD/ACLF trial has been performed, the
Steroids or Pentoxifylline for Alcoholic Hepatitis trial.21
Furthermore, a recent HAS infusion in sepsis study did
not achieve the 30 g/L target22 and a HAS in cirrhosis trial
was stopped early because of potential adverse effects.
Therefore, a feasibility study was essential to determine
whether our suggested protocol was achievable, effective,
and did not suggest safety concerns. We did not include a
standard-care arm in this feasibility trial and the study
was not powered to detect clinical outcomes.
Materials and Methods
Study Design
We conducted this prospective, multicenter, open-
label, feasibility trial of targeted 20% HAS infusions in
UK AD/ACLF patients to inform the design of a phase 3
RCT. A protocol report was published23 and the full
protocol is available online. All authors had access to the
study data, and reviewed and approved the manuscript.
Inclusion Criteria
All patients admitted to the hospital with AD or
severe worsening of the complications of cirrhosis, who
were older than age 18 years, with a serum albumin level
less than 30 g/L, a predicted hospital admission longer
than 5 days, and that were for full active management at
admission were eligible. Patients were recruited within
72 hours of admission; the full inclusion criteria are
listed in Supplementary Table 1. We sought written
informed consent from patients or their representatives
if patients were lacking decision-making capacity.
Research ethical approval was granted by London-Brent
research ethics committee (ref: 15/LO/0104).
Intervention
In-patients received daily 20% HAS infusions intra-
venously for the treatment period, with a maximum of 14
days or until the patient was considered medically ﬁt for
discharge if fewer than 14 days. The volume of HAS
prescribed was determined by the patients’ serum al-
bumin level that day (Supplementary Table 2), based on
the Albumin Replacement in Patients with Severe Sepsis
study22 and clinical experience. All clinicians could
deviate from the suggested regimen, but were requested
to document their reasons for doing so.
Clinical Outcomes
The primary end point was daily serum albumin
value for the treatment period. Success was deﬁned as
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min levels at or greater than 30 g/L on at least one third
of the days in the study with recorded levels.
The rates of infection, organ dysfunction (for deﬁni-
tions see Supplementary Tables 3 and 4), and in-hospital
mortality, the component elements of the planned
composite end point for the RCT, also were recorded.
Deﬁnitions of organ failure were chosen from the
European Foundation for the study of chronic liver failure
Sequential Organ Failure Assessment score.24 We used a
recent deﬁnition of renal dysfunction in cirrhosis25
reﬂecting deterioration in patient renal function rather
than static values. Because studies have shown that up to
50% of liver patients considered to be infected may have
negative microbiological culture,26 we used antibiotic
initiation as a surrogate for infection diagnosis. A subset
of patients had clinical, biochemical, and microbiological
data recorded for validation of infection diagnosis.
Data were summarized further within groups deﬁned
by baseline serum albumin levels (<20, 20–25, and
26–29 g/L) to investigate any apparent differences in
outcome by group. This subgroup analysis was consid-
ered crucial to potentially identify whether any protocol
amendments were necessary. The information was
summarized for the total volume of albumin infused and
of ﬂuid administered, days spent in the intensive care
unit, and the duration of hospital stay. Safety was
assessed by our Independent Data Monitoring Commit-
tee (IDMC) who considered the number of serious
adverse events (SAEs) reported during the trial.
Independent Data Monitoring Committee
The IDMC received monthly updates of the SAEs to
ensure robust monitoring and met every 6 months to
report to the Trial Steering Committee. The SAEs were
recorded from entry into study until discharge or the end
of treatment.
Statistical Methods
A sample size of 80 ensured 72 evaluable patients
(this assumed a 10% loss to follow-up evaluation/with-
drawal), with a probability of achieving 44 or more
successes of 80%. Calculations assumed each patient had
a 65% chance of albumin level being 30 g/L or greater
on at least one third of the days when the level was
recorded. If 44 successes or more were observed, then a
single-sided 90% CI would suggest that the true rate is
higher than 50%. Because this was a feasibility study, the
emphasis was on producing relevant data summaries
rather than on formal modeling or hypothesis testing. All
analyses were undertaken by an intention-to-treat,
including all consented and enrolled patients for whom
outcomes were available, and according to a prespeciﬁed
(approved before database lock) statistical analysis plan
that is included in the Supplementary Materials and
Methods section.Trial Registration
The trial is registered with the European Medicines
Agency (European Clinical Trials Database 2014-002300-
24) and adopted by National Institute for Health Research
(International Standard Randomised Controlled Trial
Number 14174793).
Results
Recruitment and Baseline Clinical
Characteristics
Between May and December 2015, there were 517
AD/ACLF patients who were screened at 10 UK hospitals,
with 124 eligible for inclusion and 80 enrolled. One pa-
tient was excluded from analysis (Figure 1A) because
their baseline albumin level was greater than 30 g/L.
Their mean age was 53.4 years, with a male predomi-
nance (66%), and alcohol was the primary underlying
cause in 96% (Table 1). The mean Model for End-stage
Liver Disease score was 20.9 (SD, 6.62), 17 of 79
patients had 1 or more extrahepatic organ dysfunction(s)
at baseline according to our deﬁnitions, and 21 patients
had ACLF grades 1 to 3 according to the European As-
sociation for the Study of the Liver-CLIF deﬁnition.27
Sixty-seven percent of patients had baseline albumin
levels less than 25 g/L. The mean time from admission to
enrollment was 1.8 days. The most common reasons for
ineligibility during screening were as follows: (1) albumin
level of 30g/Lorgreater; (2) admissionmore than72hours
before screening; and (3) predicted hospital stay of fewer
than 5 days. The most common reasons for nonparticipa-
tion of eligible patients were as follows: (1) patient
declined; (2) informed consent was not possible; and
(3) the site was unable to randomize within 72 hours.
Targeted 20% Human Albumin Solution
Infusions Increase Serum Albumin Level to
30 g/L or More
A total of 68 of 79 patients achieved a serum albumin
level of 30 g/L or greater on at least one third of days
recorded, providing a success rate of 86% (95% CI,
76%–92%) (Table 2, and Supplementary Table 5). All
patients enrolled contributed to the analysis. The
regimen was effective across all serum albumin sub-
groups, with the highest success in the 26 to 29 g/L
group (96% success; 95% CI, 80%–100%) compared
with less than 20 g/L (50% success; 95% CI, 19%–81%).
The mean treatment length was 10.3 days and a mean of
1042 mL 20% HAS (SD, 678 mL) was administered;
more than 50% of patients had their albumin level
restored to 30 g/L or greater after 3 days, and more than
75% after 7 days. Deaths (n ¼ 8) or SAEs (n ¼ 12)
during the trial period were not considered directly
related to the HAS infusions by the IDMC (Table 3). Sixty-
four percent of administrations were in accordance with
Figure 1. Targeted 20% HAS infusions according to the Albumin To PrevenT Infection In Chronic LiveR FailurE protocol
effectively increase serum albumin to 30 g/L or greater. (A) Albumin To PrevenT Infection In Chronic LiveR FailurE feasibility
study Consolidated Standards of Reporting Trials ﬂowchart. (B) Median serum albumin levels throughout the study period.
(C–E) Data are expressed according to baseline serum albumin (alb) level. Day 1 was deﬁned as the time of recruitment
(pretreatment). The horizontal line in the boxes indicates the median, the top and bottom of the box indicate the interquartile
range; dots represent individual outliers, deﬁned as data points greater than 1.5 times the interquartile range from the median.
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suggested dose (Supplementary Table 6). No patient
underwent a liver transplantation. On 161 of 657 occa-
sions, 20% HAS was not administered despite a serum
albumin level less than 35 g/L, suggesting an adherence
rate of 75%.
Infection, Organ Dysfunction, Death, and
Duration of Hospital Stay
Clinical end pointswere reported fromdays 3 to 15 after
study entry (termed the treatment period) to ensure at least
24 hours since the patients ﬁrst received 20% HAS treat-
ment before measuring possible outcomes. The average
time from admission to death or discharge was 16.9 days
(SD, 15.7 d; range, 2–102 d). Forty-two of 817 patient days
recorded were in the intensive care unit (approximately
5%). SupplementaryTable7 shows thedata fordays2 to15.
Infection deﬁned by new/change in antibiotic
prescription. Forty-one of 79 patients were prescribedantibiotics at recruitment to the study, with 27 of 41
given an infection diagnosis by their clinician. During the
treatment period, 21 of 79 patients (27%) were diag-
nosed with a new infection (Table 4). The patients who
had been prescribed antibiotics on admission had
increased subsequent nosocomial infection rates
compared with those who were not prescribed antibi-
otics on admission (24% vs 8%, respectively).
Infection case report forms were completed for 35 of
the antibiotic prescriptions (either at baseline or after
recruitment). A blinded microbiology review showed
that 4 of 35 did not fulﬁll infection predeﬁned criteria
(Supplementary Table 4). Supplementary Table 8 details
these case report form data.
Extrahepatic organ dysfunction. Overall, 7 of 79 (9%)
patients met renal dysfunction criteria, 19 of 79 (24%)
met respiratory dysfunction criteria, 15 of 79 (19%) met
circulatory dysfunction criteria, and 1 of 79 (1%)
met cerebral dysfunction criteria during the treatment
period.
Table 1. Baseline Demographics and Clinical Characteristics
of the Analysis Population (n ¼ 79)
Characteristic Mean (SD)
Age, y 53.41 (11.63)
Serum albumin level, g/L 23.95 (3.51)
Days since admission 1.81 (0.88)
MELD 20.90 (6.62)
Creatinine level 91.2 (78.2)
n (%)
Male 52 (66)
Admitted to ICU 2 (3)
Prescribed antibiotics 41 (52)
Diagnosis of infection 27 (34)
Etiology of cirrhosisa
Alcohol 76 (96)
Hepatitis B 1 (1)
Hepatitis C 11 (14)
NAFLD 4 (5)







Grade 0 58 (73)
Grade 1 11 (14)
Grade 2 6 (8)
Grade 3 4 (5)
ACLF, acute-on-chronic liver failure; ICU, intensive care unit; MELD, Model for
End-stage Liver Disease; NAFLD, nonalcoholic fatty liver disease.
aSome patients have more than 1 cirrhosis etiology.
bOrgan dysfunction at baseline was determined according to the following
criteria: renal, creatinine level > 133 mmol/L; respiratory, oxygen saturations
divided by inspired oxygen < 357; circulatory, mean arterial pressure < 60 mm
Hg or patient is receiving inotropic/vasopressor support; cerebral, grade III or
IV encephalopathy.
cAccording to European Association for the Study of the Liver-CLIF criteria.
Table 3. Details of Reported Serious Adverse Events
Throughout Trial Treatment Period (Days 1–15)
SAE description Events, n
New ascites 1
Renal impairment 1
Variceal bleeding (death) 3
Variceal bleeding (death) 1
Pneumonia (death) 1
Death (decompensated cirrhosis) 4
Bronchogenic carcinoma and pleural effusion (death) 1
Total deaths in trial treatment period 8 (10%)
SAE, serious adverse event.
Table 4. Number of Patients Reported as Having Infection,
Organ Dysfunction, and Death During the Trial
Treatment Period
End point
Patients, n, days 3–15
of trial treatment
752 China et al Clinical Gastroenterology and Hepatology Vol. 16, No. 5Death. Five patients (6%) died during the treatment
period, and 14 patients died within 30 days of study
entry (18%).
The planned composite end point for the randomized
controlled trial. Thirty-eight of 79 patients (48%)
reached the planned composite end point during the
treatment period (Table 5). Of these, the breakdown of
components that triggered the composite end point ﬁrst
were as follows.Table 2. Primary Outcome of Daily Albumin Level for
Subgroups Deﬁned by Baseline Albumin Level (<20,





(%), mean (95% CI)
<20 5/10 50 (19–81)
20–25 38/43 88 (75–96)
26–29 25/26 96 (80–100)















sup1. Thirteen patients had an infection recorded as the
ﬁrst end point component, with 8 patients developing
subsequent organ dysfunction and 4 of these patients
had died by 30 days. Of the 5 patients who did not
develop subsequent organ dysfunction, 1 patient died
within 30 days. Themedian hospital staywas 19 days
after infection diagnosis (Supplementary Table 9).
2. Three patients developed renal dysfunction as the
ﬁrst end point, of these, 2 patients died during
admission and the other patient was alive at 30 days.
A further4patientsdevelopedrenaldysfunction after
another organ dysfunction, with 2 patients dying as
inpatients (1 patient during the treatment period),
another patient shortly after discharge, and the other
patientwas alive at 30 days (SupplementaryTable 9).
3. Twelve patients developed respiratory dysfunction
as the ﬁrst end point, with 5 of these patients
triggering subsequent other end points (4
infections, 1 died). Of the 7 patients who developed
solely respiratory dysfunction, the vast majority
had a good outcome, with 6 alive at 30 days, 1
death during admission, and a median stay from







TE. Data were recorded throughout the study period, but data were re-
ted from day 3 of treatment onward so that patients had at least 24 hours of
venous 20% HAS treatment. Patients may have achieved more than 1 end
t (eg, infection and death). Organ dysfunction at baseline was determined
ording to the following criteria: renal, creatinine level > 133 mmol/L; respi-
ry, oxygen saturations divided by inspired oxygen < 357; circulatory, mean
rial pressure < 60 mm Hg or patient is receiving inotropic/vasopressor
port; cerebral, grade III or IV encephalopathy.
Table 5. Incidence of Planned and Revised RCT Composite
End Point and Contributing Components (Days 3–15
of Trial Treatment)


















RCT, randomized controlled trial.
aInfection indicated by new or change in prescription for antibiotics.
bOrgan dysfunction at baseline was determined according to the following
criteria: renal, creatinine level > 133 mmol/L; respiratory, oxygen saturations
divided by inspired oxygen < 357; circulatory, mean arterial pressure < 60 mm
Hg or patient is receiving inotropic/vasopressor support; cerebral, grade III or
IV encephalopathy.
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nosis with respiratory dysfunction (Supplementary
Table 9).
4. Nine patients developed circulatory dysfunction as
the ﬁrst end point, with 3 patients triggering other
end points, and 1 patient died during admission.
All 6 patients who solely developed circulatory
dysfunction were alive at 30 days, and the median
stay after circulatory dysfunction diagnosis was 7
days, with 2 patients discharged within 2 days of
diagnosis (Supplementary Table 9).
5. One patient died without previously triggering
another end point.
Only 1 patient developed grade 3 hepatic encepha-
lopathy after an infection, therefore no brain dysfunction
diagnoses contributed to the end point.
Serious Adverse Events
The SAEs (n ¼ 13) during treatment were deemed to
be unrelated to HAS by our IDMC (Supplementary
Table 10).
Discussion
Targeted albumin infusions effectively increased
serum albumin levels to 30 g/L or greater in hospitalized
AD/ACLF patients; a level below which we previously
identiﬁed as predicting immune dysfunction.18 Our
infusion protocol was effective, acceptable at multiple
sites, and deemed safe by the IDMC.Our suggested protocol allowed dose reduction (eg, if
safety concerns), as clinical practice remains variable.28
We achieved the primary end point with 75% adher-
ence, increasing and maintaining albumin even in
patients with very low baseline values. Although a single-
arm study, the rates of adverse events of particular
concern were low, in particular there were no reports of
pulmonary edema. Four variceal bleeds were reported,
which potentially can be precipitated by increased portal
pressure after albumin. Although not reported in previ-
ous albumin trials, this remains a concern. However, a
5% incidence during treatment is similar to expected
rates.21,24,29 The IDMC had no reason to alter our
regimen; the absolute safety of our albumin regimen will
be determined in our RCT vs standard care.
Our inclusion criteria were broad and straightfor-
ward and selected patients with almost exclusively
alcohol-induced liver disease, a substantial spread of al-
bumin values, and an ACLF score of 1 to 3 in 25% of
cases. We reasoned that our intervention would be more
successful in ward-based patients rather than in patients
with multi-organ failure, and these criteria appeared to
capture exactly this population. The majority were
recruited within 2 days of admission, which is crucial
because early intervention is widely believed to be imper-
ative to improve outcomes in critically ill patients. As a trial
aimed at the prevention of nosocomial infection, the pri-
mary composite end point will be reported from day 3
onward in line with established diagnostic criteria, which
also ensures at least 24 hours of 20% HAS therapy. The
observed in-hospital and 30-day mortality were similar to
previous studies.21,30,31 Survival at 3 and 6 months were
not recorded but will be reported in the RCT. We included
a medically ﬁt for discharge category at the end of the
trial period because many patients have social needs that
prolong hospital stay beyond their medical needs.
Our RCT primary composite end point was planned as
infection, organ dysfunction, and death because infection
commonly triggers organ dysfunction and the combina-
tion substantially increases mortality. However, the
feasibility of recording such data in a ward-based trial of
AD/ACLF at multiple sites is not commonplace. Other
than renal failure,32 there is also no universally accepted
deﬁnition for early (reversible) organ dysfunction/fail-
ures in patients with cirrhosis.
A robust diagnosis of infection in AD/ACLF is chal-
lenging because of the high rates of culture-negative
sepsis.26 The on-site clinician-reported infection rate on
admission was 34%, which is in line with other studies;
however, antibiotics were prescribed in substantially
more patients (52%). This perhaps reﬂects a tendency to
overprescribe, as reported elsewhere,33,34 and therefore
using a new/changed antibiotic prescription as a surro-
gate for infection diagnosis, as originally intended,
appeared subject to potential bias and this cannot be
standardized across multiple sites. In the RCT we
therefore will deﬁne infection according to clinician
diagnosis, triggering completion of an infection case
754 China et al Clinical Gastroenterology and Hepatology Vol. 16, No. 5report form, with a substantial proportion blindly scruti-
nized by a microbiology panel. This approach appeared
feasible in a subset of 35 patients tested. Our data suggest
that patients prescribed antibiotics at admission have a
3 times increased risk of subsequent nosocomial infection.
This has been reported previously6 and justiﬁes inclusion
of these patients in an RCT to prevent infection; further-
more, an antibiotic prescription will be included in strat-
iﬁcation at randomization. Whether our reported
nosocomial infection rate of 27% represents a beneﬁcial
effect of 20%HAS infusionswill be determined in the RCT.
Renal dysfunction uses an objective measurement,
creatinine, and patients developing this had a poor
prognosis, as expected. Renal dysfunction rates were
lower than anticipated (9% vs up to z60%35), perhaps
related to additional ﬂuid.30 Cerebral, respiratory, and
cardiac dysfunctions were recorded daily. Only 1 patient
developed cerebral dysfunction reﬂecting severe hepatic
encephalopathy (grade 3), suggesting under-reporting,
and objective assessment of encephalopathy is recog-
nized as challenging.34,36 The majority of patients who
solely triggered respiratory and cardiovascular end
points had a good outcome, with several discharged
within a few days. This is counterintuitive because organ
dysfunction is a key predictor of poor prognosis.
Assessment may be subject to technical difﬁculties such
as a standard-size blood pressure cuff for patients with
sarcopenia and a oxygen saturation/fraction of inspired
oxygen recording of respiratory dysfunction is inﬂu-
enced greatly by the amount of oxygen delivered by
mask or nasal cannulae. We believe our data cast sig-
niﬁcant doubt over whether these dysfunctions can be
recorded accurately in largely ward-based patients
across multiple sites and therefore precludes use as part
of our RCT primary composite end point; although these
will be reported. Table 5 shows the incidence of our
revised primary composite end point of infection, renal
dysfunction, and mortality.
In summary, our multicenter feasibility study repre-
sents a highly pragmatic feasibility study in a challenging
group of patients. The data presented conﬁrm that our
suggested protocol was deliverable across multiple
sites and the dosing regimen increased serum albumin
without signiﬁcant safety concern. Albumin To PrevenT
Infection In Chronic LiveR FailurE stage 2 is a multicenter,
open-label, interventional RCT and began recruitment in
April 2016. This is a phase 3 RCT to verify whether
targeting a serum albumin level of 35 g/L or greater in
patients admitted with acutely decompensated cirrhosis
using repeated intravenous infusions of 20% HAS will
reduce the incidence of infection, renal dysfunction, and
mortality for the treatment period (maximum 14 days, or
discharge if <14 days) compared with standard medical
care. The trial will recruit 866 patients at more than 30
sites across the United Kingdom.
Large multicenter studies in patients with advanced
liver disease rarely are performed and require signiﬁcant
resources. This feasibility study has enabled substantialimprovement in design and end point deﬁnition/selec-
tion as well as providing important safety information
and mechanistic insight. This approach could serve as a
model for future trials in such patients.Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at https://doi.org/10.1016/j.cgh.2017.09.012.References
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Trial Management and Monitoring
Research steering group. The Research Steering
Group operates on behalf of the funders to ensure that
appropriate milestones have been met in the delivery of
the trial. It consists of the chief investigator, an inde-
pendent expert, and representatives of the Wellcome
Trust and Department of Health.
Trial Management Group. The Trial Management
Group comprises the chief investigator, Clinical Research
Fellow, Clinical Project Manager, Trial Statistician, Trial
Manager, Data Manager, Health Economist, and 5 trial
site Principal Investigators. The Trial Management Group
is responsible for developing the design, coordination,
and strategic management of the trial.
Trial Steering Committee. The Trial Steering Com-
mittee is the independent group responsible for over-
sight of the trial to safeguard the interests of trial
patients. The Trial Steering Committee provides advice to
the chief investigator, Clinical Trials Unit, funder, and
sponsor on all aspects of the trial through its indepen-
dent chair.Independent Data Monitoring Committee. The IDMC is
responsible for safeguarding the interests of trial pa-
tients, monitoring the accumulating data, and making
recommendations to the Trial Steering Committee on
whether the trial should continue as planned. It com-
prises a clinical chair (independent hepatologist), inde-
pendent gastroenterologist, and an independent
statistician, all with expertise in Clinical Trials.
The participating hospitals and personnel were
as follows: Dr G. Wright at Basildon University Hos-
pital, 17 patients recruited; Dr J. Portal at Bristol Royal
Inﬁrmary, 14 patients recruited; Dr L. Corless at Hull
Royal Inﬁrmary, 11 patients recruited; Dr C. Lye Ch’ng
at Singleton Hospital Swansea, 8 patients recruited;
Dr P. Richardson at Royal Liverpool University
Hospital, 7 patients recruited; Dr S. McPherson at
Newcastle Freeman Hospital, 6 patients recruited;
Dr Y. Kallis at Royal London Hospital, 6 patients
recruited; Professor J. Metcalf at North Tees and
Hartlepool, 6 patients recruited; Professor R. Jalan
at Royal Free Hospital, 3 patients recruited; and
Dr A. Elsharkawy at University Hospitals Birmingham,
2 patients recruited.
Supplementary Table 1. ATTIRE Feasibility Study Patient Inclusion and Exclusion Criteria
Inclusion criteria Exclusion criteria
All patients admitted to the hospital with acute onset or worsening of
complications of cirrhosis
Advanced hepatocellular carcinoma with life expectancy of <8
weeks
Older than 18 years of age Patients who will receive palliative treatment only during their
hospital admission
Predicted hospital admission>5 days at trial enrollment, which must
be within 72 hours of admission
Patients who are pregnant
Serum albumin level <30 g/L at screening Known or suspected severe cardiac dysfunction
Documented informed consent to participate (or consent given by a
legal representative)
Any clinical condition that the investigator considers would make the
patient unsuitable for the trial
The patient has been involved in a clinical trial of Investigational
Medicinal Products within the previous 30 days that would
impact their participation in this study
Trial investigators unable to identify the patient (by NHS number)
ATTIRE, Albumin To PrevenT Infection In Chronic LiveR FailurE; NHS, National Health Service.
Supplementary Table 2. Suggested Daily Dosing Protocol
for 20% HAS Administration




Suggested volume of 20%







Supplementary Table 3. Deﬁnitions of Extrahepatic Organ
Dysfunction
Organ Deﬁnition of new dysfunction
Renal Serum creatinine level increases by 50% as
compared with serum creatinine level at
baseline
Respiratory Any single point increase in oxygen saturations
divided by inspired oxygen as classiﬁed on the
following scoring system compared with
oxygen saturations divided by inspired oxygen
at randomization: 0, >357; 1, >214 to 357; 2,
214 or mechanical ventilation
Circulatory MAP decreases to <60 mm Hg, OR patient is
started on inotropic/vasopressor support
If the patient has MAP < 60 mm Hg at baseline,
they will need to be started on inotropic/
vasopressor support to reach this end point
Cerebral Grade III (drowsy) or grade IV encephalopathy
(coma) using the Westhaven criteria to grade
hepatic encephalopathy
If the patient has grade III encephalopathy
(somnolent but rousable at baseline), they will
need to progress to grade IV to reach this end
point
NOTE. Organ dysfunction at baseline was determined according to the
following criteria: renal, creatinine level > 133 mmol/L; respiratory, oxygen
saturations divided by inspired oxygen < 357; circulatory, MAP < 60 mm Hg or
patient is receiving inotropic/vasopressor support; cerebral, grade III or IV
encephalopathy.
MAP, mean arterial pressure.
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Supplementary Table 4. Deﬁnition of Infections–Infection Can Be Deﬁned According to the Following Peer-reviewed
Criteria6,14
Type of infection Deﬁnition
Spontaneous bacteremia Positive blood cultures without a source of infection
SBP Ascitic ﬂuid polymorphonuclear cells >250 cells/mm3
Lower respiratory
tract infections
New pulmonary inﬁltrates in the presence of: at least 1 respiratory symptom (cough, sputum
production, dyspnea, pleuritic pain), with at least 1 ﬁnding on auscultation (rales or
crepitation) or 1 sign of infection (core body temperature >38C or <36C, shivering, or
leukocyte count >10,000/mm3 or <4000/mm3) in the absence of antibiotics
Clostridium difﬁcile infection Diarrhea with a positive C difﬁcile assay
Bacterial enterocolitis Diarrhea or dysentery with a positive stool culture for Salmonella, Shigella, Yersinia,
Campylobacter, or pathogenic Escherichia coli
Soft-tissue/skin infection Fever with cellulitis
Urinary tract infection Urine white blood cell count >15/high-power ﬁeld with either positive urine Gram stain or culture
Intra-abdominal infections Diverticulitis, appendicitis, cholangitis, and so forth
Other infections Not covered in 1–8
Fungal infections
Nosocomial infections Are diagnosed after 48 hours of admission, whereas secondary infections are diagnosed after a
separate ﬁrst infection has been documented
SBP, spontaneous bacterial peritonitis.
Supplementary Table 5. Daily Albumin Level (g/L) From Day 1 (Baseline) to Day 15: All Patients
Albumin level, g/L
Day
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Median 25 28 31 31 32 31 31 32 32 33 33 32 32 32 31
IQR 22–27 26–32 28–33 28–33 30–33 29–34 30–34 31–34 31–34 31–35 31–35 31–34 31–35 30–36 30–34
Range 12–29 19–38 21–37 24–39 23–41 24–39 24–41 22–38 22–38 26–37 27–38 27–40 25–39 24–39 28–39
Mean (SD) 24 (4) 28 (4) 30 (4) 31 (3) 32 (3) 31 (3) 32 (3) 32 (3) 32 (3) 33 (3) 33 (3) 32 (3) 33 (3) 33 (3) 32 (3)
N 79 74 63 57 53 51 51 51 41 34 35 31 32 27 20
30, N 0 30 35 36 40 38 40 47 38 30 31 25 29 25 18
Study, N 79 77 74 72 65 60 57 55 48 44 43 42 39 34 28
IQR, interquartile range.
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Supplementary Table 6. Number of Occasions Albumin Was Neither Prescribed nor Administered When Albumin
Level <35 g/L
Days 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Total
Neither prescribed nor administered 1 5 10 10 11 7 9 4 9 10 13 11 7 7 114
Prescribed but not administered 10 6 8 2 1 2 2 3 2 4 2 1 3 1 47
Administered but not prescribed 2 2 1 1 3 0 0 0 0 2 0 2 1 0 14
Total 13 13 19 13 15 9 11 7 11 16 15 14 11 8 175
Albumin level <35, N 79 73 64 58 56 48 48 44 40 32 29 34 28 24 657
Supplementary Table 7. Incidence of Proposed Composite
End Point and Contributing
Components, With and Without
Respiratory/Circulatory
Dysfunctions From Days 2–15
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Supplementary Table 8. Details From Infection Data Matched to 35 of 62 Antibiotic Prescriptions
Classiﬁed infection Times conﬁrmed, na
Antibiotic sensitivity
Resistant Sensitiveb Unknown
Spontaneous bacterial peritonitis 4 0 1 3
Pneumonia 6 0 1 5
Cellulitis 4 0 1 1
Bacterial enterocolitis 1 1c 0 0
Fungal infection 1 0 0 1
Spontaneous bacteremia 7 2d 2 3
Other infection 8 3e 0 5
Urinary tract infection 0 N/A
Other intra-abdominal infection 0
C difﬁcile 0
Total 31 6 5 18
aSome patients had multiple infections (4 of 35 cases did not meet criteria for an infection diagnosis).
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Supplementary Table 9.Outcomes for Individual Patients Who Triggered the Planned Composite End Point for the RCT
















Respiratory 13 13 0 Yes
Respiratory 7 23 16 Yes
Respiratory 15 16 1 Yes
Respiratory 8 23 15 No
Respiratory 3 12 9 Yes
Respiratory 9 17 8 Yes
Respiratory 4 6 2 Yes
Respiratory 3 Infection 9 15 12 Yes
Respiratory 3 Infection 5 28 25 Yes
Respiratory 3 Infection 6 17 14 Yes
Respiratory 3 Death 3 3 0 No
Respiratory 3 Infection 5 Circulation 9 23 20 Yes
Circulatory 6 15 9 Yes
Circulatory 9 21 12 Yes
Circulatory 3 3 0 Yes
Circulatory 3 6 3 Yes
Circulatory 3 15 12 Yes
Circulatory 9 14 5 Yes
Circulatory 4 Infection 8 32 28 Yes
Circulatory 11 Infection 15 27 16 Yes
Circulatory 10 Renal 12 14 8 Yes
Renal 3 11 8 Yes
Renal 3 Infection 4 Death 5 5 2 No
Renal 5 Infection þ
respiratory þ
circulatory
8 Cerebral 9 24 19 No
Infection 3 31 28 No
Infection 11 18 7 Yes
Infection 8 13 5 Yes
Infection 3 22 19 Yes
Infection 13 43 30 Yes
Infection 3 88 85 Yes
Infection 13 Respiratory 13 101 88 Yes
Infection 3 Respiratory 3 23 20 No
Infection 3 Circulatory 10 14 11 Yes
Infection 7 Renal 14 Death 15 15 8 No
Infection 3 Circulatory 5 Respiratory 6 34 31 Yes
Infection 3 Respiratory þ
circulatory
3 Renal 4 13 10 No







Death 6 6 1 No
Supplementary Table 10. SAEs as Individually Reported




New ascites 1 Unrelated
Renal impairment 1 Unrelated
Variceal bleeding (death) 3 Unrelated
Variceal bleeding (death) 1 Unlikely to be
related
Pneumonia (death) 1 Unrelated
Death (decompensated cirrhosis) 4 Unrelated
Bronchogenic carcinoma and pleural
effusion (death)
1 Unrelated
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